Shah Kekul B, Wu Tzu G, Wilhelmus Kirk R, Jones Dan B
Sid W. Richardson Ocular Microbiology Laboratory, Cullen Eye Institute, Department of Ophthalmology, Baylor College of Medicine, Houston, Texas, USA.
Cornea. 2003 Jan;22(1):33-6. doi: 10.1097/00003226-200301000-00008.
To determine the in vitro antifungal activity of voriconazole, a new triazole, compared with other polyene and imidazole antifungal agents against corneal isolates of Scedosporium apiospermum.
Macro-broth dilution susceptibility testing was performed on five isolates of S. apiospermum obtained from patients with keratomycosis to determine the minimal inhibitory concentrations (MICs) for amphotericin B, natamycin, ketoconazole, itraconazole, and voriconazole. The use of oral voriconazole in the management of a patient with posttraumatic S. apiospermum keratitis is described.
S. apiospermum is generally resistant to commonly used topical ophthalmic antifungal agents. The MIC of voriconazole was 0.5 microg/mL, a concentration lower than that of other imidazoles.
Voriconazole has promising activity against and may prove useful in the management of fungal keratitis.
将新型三唑类药物伏立康唑与其他多烯类和咪唑类抗真菌药物进行比较，以确定其对角膜分离的尖端赛多孢菌的体外抗真菌活性。
对从角膜真菌病患者中分离出的5株尖端赛多孢菌进行宏量肉汤稀释药敏试验，以确定两性霉素B、那他霉素、酮康唑、伊曲康唑和伏立康唑的最低抑菌浓度（MIC）。描述了口服伏立康唑治疗一名创伤后尖端赛多孢菌角膜炎患者的情况。
尖端赛多孢菌通常对常用的局部眼科抗真菌药物耐药。伏立康唑的MIC为0.5微克/毫升，该浓度低于其他咪唑类药物。
伏立康唑对真菌性角膜炎具有良好的活性，可能在真菌性角膜炎的治疗中发挥作用。
